Title
Coulter BME Seminar Series
Sections
The Coulter BME Seminar Series brings leading voices in biomedical engineering to Georgia Tech and Emory University for thought-provoking talks that spark collaboration and inspire innovation. Featuring renowned researchers, clinicians, and industry experts, these seminars explore emerging trends, groundbreaking discoveries, and interdisciplinary approaches to advancing human health.
Open to students, faculty, and the broader research community, the series fosters dialogue across institutions and disciplines—connecting people and ideas that drive the future of biomedical engineering.
2025-2026 Series
Fikri Avci Ph.D.
Associate Professor, Department of Biochemistry
Emory University
Friday, Sept. 19, 2025
1 p.m.
Emory University HSRB II, N100
Immune Interactions of Carbohydrate Antigens in Health and Disease
Abstract:
The Avci Lab is an interdisciplinary research group addressing problems at the interface of immunology and glycobiology. Our objective is to explore treatment of and protection from human diseases by understanding key molecular and cellular interactions between the immune system and carbohydrate antigens. Our research program elucidates the immune mechanisms involved in carbohydrate-mediated effector and regulatory immune responses, and designs and tests prophylactic and therapeutic agents for infectious diseases, autoimmune diseases, and cancer.
Bio:
Fikri Avci is an associate professor in the Department of Biochemistry at Emory University School of Medicine. Prior to joining the faculty at Emory in 2022, Dr. Avci was an associate professor in the Department of Biochemistry and Molecular Biology at University of Georgia. Dr. Avci is a member of the Cancer Immunology Research Program at Winship Cancer Institute and a member of the Emory Vaccine Center.
Kathryn A. Whitehead Ph.D.
Professor, Department of Chemical Engineering and Department of Biomedical Engineering
Carnegie Mellon University
Lipid nanoparticles for RNA delivery: Enablers of a new wave of genetic medicine
Abstract:
Messenger RNA (mRNA) therapeutics have taken center stage thanks to the successful deployment of the SARS-CoV2 mRNA vaccines in hundreds of millions of people worldwide. These vaccines were made possible by a herculean effort to overcome the most significant barriers that have hindered translational efforts. Arguably, the largest challenge has been that RNA molecules do not readily enter their cellular targets within the body. This is because they are large (104 – 106 g/mol) and negatively charged; they do not have favorable biodistribution properties nor an ability to cross the cell membrane of target cells. In response to these issues, industrial and academic laboratories, including my own, have created lipid nanoparticles that spontaneously package RNA and deliver the RNA to key cellular targets in vivo. Here, I will describe biodegradable, ionizable lipid-like materials called ‘lipidoids’ that my lab has used to create RNA-loaded lipid nanoparticles that induce protein expression in a variety of tissues. This talk will describe how simple changes in nanoparticle chemistry and route of administration cause dramatic shifts in efficacy and tropism, allowing the targeting of organs such as the lungs, pancreas, and brain. Together, these data advance our understanding of lipid nanoparticle chemistry and are expected to contribute to the successful formulation of next-generation mRNA therapies.
Bio:
Kathryn (Katie) Whitehead is a Professor in the Departments of Chemical Engineering and Biomedical Engineering (courtesy) at Carnegie Mellon University. Her lab develops drug delivery systems for RNA, proteins, and applications in maternal and infant health. She obtained bachelor and doctoral degrees in chemical engineering (Univ. of Delaware; Univ. of California, Santa Barbara) before an NIH Postdoctoral Fellowship at MIT. Prof. Whitehead is the recipient of numerous awards, including the NIH Director’s New Innovator Award, the DARPA Director’s Fellowship, and the ASEE Curtis W. McGraw Research Award. She has also received the Controlled Release Society’s Young Investigator Award and served on its Board of Directors. Prof. Whitehead is an elected Fellow of the American Institute for Medical and Biological Engineering and the Controlled Release Society. In 2021, she gave a TED talk on the lipid nanoparticles (i.e., “fat balls”) used in the in the COVID-19 mRNA vaccines. Her publications have been cited ~15,000 times, and her patents have been licensed and sublicensed for reagent and therapeutic use.